Edition:
United States

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

9.80USD
15 Dec 2017
Change (% chg)

$0.03 (+0.31%)
Prev Close
$9.77
Open
$9.92
Day's High
$9.92
Day's Low
$9.78
Volume
15,731
Avg. Vol
7,965
52-wk High
$14.18
52-wk Low
$5.02

Latest Key Developments (Source: Significant Developments)

Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Obseva Sa ::OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR.OBSEVA SA - ‍OBSEVA EXPECTS TO ANNOUNCE PRELIMINARY RESULTS FROM 60 PATIENTS IN PART B OF PROLONG TRIAL IN LATE 2018​.  Full Article

ObsEva SA files for resale of up to 7.5 million common shares‍​
Thursday, 9 Nov 2017 06:27pm EST 

Nov 9 (Reuters) - Obseva Sa :ObsEva SA - files for resale of up to 7.5 million common shares‍​ of co by the selling shareholders - SEC filing.  Full Article

ObsEva SA announces $60 mln private placement with existing and new investors
Tuesday, 10 Oct 2017 08:01am EDT 

Oct 10 (Reuters) - ObsEva SA : :ObsEva SA announces $60.0 million private placement with existing and new investors.ObsEva SA - ‍common shares in offering are priced at $8.00 per share.ObsEva SA - ‍net proceeds from offering are expected to be used to fund research,development of lead compound OBE2109, among others​.  Full Article

Obseva announces completion of patient recruitment
Wednesday, 6 Sep 2017 07:01am EDT 

Sept 6 (Reuters) - Obseva SA ::Obseva SA announces the completion of patient recruitment in the implant2 phase 3 clinical trial in assisted reproductive technology ahead of schedule.Obseva SA - ‍initial results are now expected in Q1 of 2018 from study​.  Full Article

Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva Sa as of August 22 2017 - SEC filing​
Thursday, 31 Aug 2017 10:25am EDT 

Aug 31 (Reuters) - :Medicxi Growth I GP limited reports a 5.30 percent passive stake in ‍obseva SA as of August 22 2017 - SEC filing​.  Full Article

Obseva SA announces completion of early stage trial evaluating endometriosis drug
Wednesday, 7 Jun 2017 07:01am EDT 

June 7 (Reuters) - Obseva sa -:Obseva SA announces the completion of a phase 1 pk/pd clinical trial evaluating different doses of obe2109 and add-back therapy.Obseva SA - all regimens in phase 1 pk/pd clinical trial were well-tolerated and no safety signal emerged.  Full Article

Obseva reports Q1 loss per share $0.58
Thursday, 18 May 2017 07:01am EDT 

May 18 (Reuters) - Obseva SA :Obseva reports first quarter 2017 financial results and business update.Q1 loss per share $0.58.Obseva SA - as of March 31, 2017, Obseva had cash and cash equivalents of $104.2 million.Obseva SA - research and development expenses were $13.1 million and general and administrative expenses were $2.7 million for quarter ended March 31, 2017.  Full Article

HBM Healthcare reports 8.14 pct passive stake in ObsEva
Monday, 13 Mar 2017 05:11pm EDT 

Obseva SA : HBM Healthcare Investments (Cayman) Ltd reports a 8.14 percent passive stake in ObsEva SA as of January 25, 2017 - SEC filing Source: (http://bit.ly/2n2yKV3) Further company coverage: [OBSV.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Obseva shares open below IPO price in market debut
Thursday, 26 Jan 2017 11:51am EST 

: Obseva SA shares open at $13.29 in debut, below IPO price of $15.00 per share Further company coverage: [OBSV.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor

* OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR